Stock GRCL GRACELL BIOTECHNOLOGIES INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Gracell Biotechnologies Inc.

Equities

GRCL

US38406L1035

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Global markets live: Booking, Diageo, AT&T, Nvidia, UBS...
Our Logo
EARNINGS AND TRADING: Astra closes Gracell buy, Amicorp "on track"
AN
AstraZeneca Completes Gracell Biotechnologies Acquisition
MT
Stifel Downgrades Gracell Biotechnologies to Hold From Buy, Trims Price Target to $10.25 From $11
MT
AstraZeneca completes acquisition of Gracell Biotechnologies
CF
AstraZeneca Closes Purchase of Gracell Biotechnologies
MT
Gracell Biotechnologies Acquisition Completed
GL
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Composite Index
CI
AstraZeneca Treasury Limited completed the acquisition of Gracell Biotechnologies Inc. from a group of shareholders.
CI
Gracell Biotechnologies Announces Shareholders Approval of Merger Agreement
AQ
Gracell Biotechnologies Inc.(NasdaqGS:GRCL) dropped from NASDAQ Biotechnology Index
CI
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
GL
Gracell Biotechnologies Announces Shareholders’ Approval of Merger Agreement
AQ
Gracell Biotechnologies Cleared for Early-Stage Trial of Prospective Multiple Myeloma Treatment
MT
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
GL
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
AQ
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T Gc012F as Early-Line Treatment of Multiple Myeloma
CI
Gracell Biotechnologies : Investor Frequently Asked Questions, dated December 29, 2023 - Form 6-K
PU
GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL
BU
AstraZeneca to Buy China’s Gracell For $1.2 Billion
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRCL Stock
  4. News Gracell Biotechnologies Inc.